While modern antiretroviral therapy (ART) improves health, prolongs survival, and reduces HIV transmission, successfully treated HIV infection remains associated with persistent inflammation and immune dysfunction ([@B1]--[@B3]). Persistent systemic inflammation is a major contributing factor to HIV-associated morbidity, including neurocognitive impairment ([Yu et al.](https://doi.org/10.3389/fimmu.2019.00814)) and non-AIDS events, which result in devastating outcomes and loss of quality of life during aging with HIV infection ([@B4], [@B5]).

The current Research Topic includes in total 11 high-quality manuscripts, ranging from host-response activation during HIV infection ([Tjitro et al.](https://doi.org/10.3389/fimmu.2018.03110)), the role of toll-like receptor (TLR)-10 ligand during HIV replication ([Henrick et al.](https://doi.org/10.3389/fimmu.2019.00482)), microRNA-19b as a regulator of CD8^+^ T cell functions during HIV infection ([Yin et al.](https://doi.org/10.3389/fimmu.2018.03140)), to potentiating the immune response via PD1 checkpoint inhibition ([Filaci et al.](https://doi.org/10.3389/fimmu.2018.02447)).

While it is known that HIV infection is characterized by a dramatic depletion of CD4^+^ T cells, a study comparing people with HIV (PWH) with age-matched uninfected controls identified specifically gamma delta (γδ)-T cells as an inflammatory driver in ART-suppressed PWH and provided evidence of distinct "inflamm-aging" processes with and without active HIV replication ([Belkina et al.](https://doi.org/10.3389/fimmu.2018.02783)). Depletion of CD4^+^ T cells together with impaired polarization of Th17 cells in the gastrointestinal tract and a massive expansion of activated CD8^+^ T cells causes CD8^+^ T cell-mediated enteropathy ([@B6]). In another study of this Research Topic authors also reported dysbiosis and translocation of microbial products in the study participants, which persisted despite long term ART mediated viral suppression ([Rhoades et al.](https://doi.org/10.3389/fimmu.2019.00463)). Specifically, the gut microbiome of long term suppressed PWH was enriched in bacterial taxa typically found in the oral cavity suggestive of loss of compartmentalization, while levels of beneficial butyrate producing taxa were reduced. Additionally, prevalence of *Prevotella* negatively correlated with CD4^+^ T-cells numbers, indicating that despite long-term adherence and undetectable viral loads, HIV infection results in significant shifts in gut microbial communities ([Rhoades et al.](https://doi.org/10.3389/fimmu.2019.00463)).

Bacteria and fungi are the two most abundant populations of the gut microbiome. While bacterial translocation has been a focus of HIV research for a number of years, fungal translocation recently came into focus as a driver of immune activation, persistent inflammation, and non-AIDS events ([@B7]--[@B12]). A review included in this supplement evaluated recent literature to untangle the respective roles of circulating lipopolysaccharide (LPS) and (1--\>3)-B-D-Glucan (BDG), which are major components of bacterial and fungal cell walls respectively and established biomarker of bacterial and fungal translocation ([Ramendra et al.](https://doi.org/10.3389/fimmu.2019.00465)). While LPS is a well-known inducer of innate immune activation, BDG is emerging as a significant source of monocyte and natural killer (NK) cell activation that contributes to immune dysfunction, and both may serve as biomarkers of disease progression and immune activation during ART ([Ramendra et al.](https://doi.org/10.3389/fimmu.2019.00465)). Further studies are needed to enhance our understanding of the consequences of elevated LPS and BDG on immune activation, which may inform novel therapeutic strategies against the occurrence of AIDS and non-AIDS events.

Another proposed marker of systemic immune activation during early and chronic HIV infection is plasma CXCL13, which is preferentially secreted by Follicular Helper T cells to attract B cells to germinal centers ([Mehraj et al.](https://doi.org/10.3389/fimmu.2019.00289)). A study included in this supplement found that in 114 PWH plasma CXCL13 levels correlated with BDG levels, were higher in those with CMV infection and increased with HIV disease progression ([Mehraj et al.](https://doi.org/10.3389/fimmu.2019.00289)). In contrast, early initiation of ART reduced plasma CXCL13 and B cell activation but without normalization. Future studies are needed to compare CXCL13 with more established biomarkers such as soluble urokinase plasminogen activator receptor (suPAR), or sTNFrI, and sTNFrII ([@B2], [@B4]) for prediction of the development of non-AIDS events.

Another study included in this supplement elucidated the role of the immunomodulatory carbohydrate-binding protein Galectin-9 in HIV transcription and in maintaining chronic immune activation during ART-suppressed HIV infection ([Colomb et al.](https://doi.org/10.3389/fimmu.2019.00267)). Interactions between cell-surface glycans and glycan-binding proteins (lectins) are key regulators of immunological functions and are involved in several cellular processes. Galectins are a class of lectins that play critical roles in T cell function, and Galectin-9 specifically has recently been recognized to play an essential role in regulating both adaptive and innate defense mechanisms ([Colomb et al.](https://doi.org/10.3389/fimmu.2019.00267)). Interestingly, the study found that uncoupling Galectin-9-mediated viral reactivation from undesirable pro-inflammatory effects, using rapamycin, may increase the potential utility of recombinant Galectin-9 within the reversal of HIV latency eradication framework ([Colomb et al.](https://doi.org/10.3389/fimmu.2019.00267)).

Finally, this Research Topic includes a paper reporting on a randomized, placebo-controlled, double-blinded trial of the TLR-3 agonist Poly-ICLC in aviremic, ART-treated PWH ([Saxena et al.](https://doi.org/10.3389/fimmu.2019.00725)). Poly-ICLC can activate immune cells and induce HIV replication in pre-clinical experiments, but this study for the first time investigated its effect in disrupting HIV latency *in vivo* while simultaneously enhancing innate immune responses. The study found that poly-ICLC was overall safe and well-tolerated ([Saxena et al.](https://doi.org/10.3389/fimmu.2019.00725)). Transcriptional analyses revealed upregulation of innate immune pathways in peripheral blood mononuclear cells (PBMCs) following Poly-ICLC treatment, including strong interferon signaling accompanied by transient increases in circulating Interferon gamma-induced protein (IP)-10 (CXCL10) levels ([Saxena et al.](https://doi.org/10.3389/fimmu.2019.00725)). These responses generally peaked by 24--48 h after the first injection and returned to baseline by day 8. Overall, CD4^+^ T cell number and phenotype were unchanged, plasma viral control was maintained and no significant effect on HIV reservoirs was observed ([Saxena et al.](https://doi.org/10.3389/fimmu.2019.00725)). These finding suggest that Poly-ICLC may be used for inducing transient innate immune responses in treated PWH indicating promise as an adjuvant for HIV therapeutic vaccines ([Saxena et al.](https://doi.org/10.3389/fimmu.2019.00725)).

Collectively, the studies described in original research and review articles in this topic describe recent advances and provide optimism for the future of treating HIV-associated inflammation. We hope these articles will stimulate further research with the ultimate goal of improving outcomes for patients with HIV infection.

Author Contributions {#s1}
====================

All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

Conflict of Interest
--------------------

MH received research funding from Gilead that was not related to this Research Topic. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Funding.** This work was supported by funds from the National Institutes of Health: AI036214, DA026306, AI064086, MH081482, MH113477, MH062512, and AI106039; and HNRP developmental grant PST-HN68. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

[^1]: Edited and reviewed by: Francesca Chiodi, Karolinska Institutet (KI), Sweden

[^2]: This article was submitted to Viral Immunology, a section of the journal Frontiers in Immunology
